HIV, fatality reviews, and syringe exchange programs

H.E.A. 1182, P.L. 112
Effective: July 1, 2020

In part: Removes acquired immune deficiency syndrome (AIDS) from the statutory definition of “exposure risk disease”. Replaces the term “AIDS” with the term “human immunodeficiency virus (HIV)” where appropriate. Replaces the term “carrier” with the term “individual with a communicable disease” where appropriate. Replaces the term “danger” with the term “risk” where appropriate. Replaces the term “spread” with the term “transmission” where appropriate. Replaces the term “HIV antibody” with “human immunodeficiency virus (HIV)” where appropriate. Requires a patient to be notified of their right to a: (1) hearing; and (2) counsel; in certain situations, involving a court ordered HIV test. Allows a health care provider or a health care provider’s employer to petition a court for an order requiring a patient to provide a blood or bodily fluid specimen in certain instances. Allows a health care provider, a health care provider’s employer, or the state department of health to request certain test results when a patient is a witness, bystander, or victim of alleged criminal activity in certain instances.

Requires a syringe exchange program to: (1) provide testing for communicable diseases and provide services or a referral for services if the individual tests positive; and (2) establish a referral process for program participants in need of information or education concerning communicable diseases or health care. Requires the state department of health to include certain information concerning syringe exchange programs in the report to the general assembly before November 1, 2020. Extends the expiration date for certain syringe exchange programs from July 1, 2021, to July 1, 2022.

Read the bill at: http://iga.in.gov/legislative/2020/bills/house/1182